Table 2.
Univariable analyses of overall survival and progression-free survival in patients with available pre-treatment C-reactive protein-to-albumin ratio data.
| OS | PFS | |||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | p | HR | (95% CI) | p | |
| Age > 60 years | 2.81 | (1.09–7.27) | 0.033 | 2.06 | (1.05–4.03) | 0.035 |
| Stage (III, IV) | 5.66 | (1.66–19.23) | 0.006 | 4.51 | (1.98–10.25) | < 0.001 |
| LDH > UNL | 6.77 | (1.57–29.14) | 0.010 | 3.19 | (1.40–7.25) | 0.006 |
| ECOG PS > 1 | 4.14 | (1.67–10.29) | 0.002 | 3.49 | (1.69–7.21) | 0.001 |
| EN > 1 | 2.31 | (0.98–5.45) | 0.055 | 1.85 | (0.97–3.51) | 0.061 |
| CAR > 0.158 | 11.22 | (2.61–48.28) | 0.001 | 5.68 | (2.50–12.93) | < 0.001 |
| Cycles of R-CHOP > 6a | 2.14 | (0.72–6.38) | 0.173 | 1.97 | (1.03–3.76) | 0.040 |
| Non-GCB typeb | 3.26 | (0.76–13.91) | 0.110 | 1.90 | (0.85–4.23) | 0.118 |
OS overall survival, PFS progression-free survival, HR hazard ratio, CI confidence interval, LDH lactate dehydrogenase, UNL upper normal limit, ECOG PS Eastern Cooperative Oncology Group performance status, EN extranodal, CAR C-reactive protein-to-albumin ratio, GCB germinal centre B-cell.
aCompared to 6.
bCompared to GCB type.